{
  "docId": "019de074-6c10-759a-a503-c8b869115e9a",
  "docSlug": "3f9321c37d26dde2e5a75b53f195ef9c",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 31,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-6c10-759a-a503-c8b869115e9a/6",
  "deckHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a",
  "deckJsonHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json",
  "deckAnchorHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.12,
        "x": 0.015,
        "y": 0.91
      },
      "kind": "image",
      "text": "Theravance Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d3670dd-b41c-49aa-ae04-11d6bf74bf41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "w": 0.25,
        "x": 0.25,
        "y": 0.16
      },
      "kind": "image",
      "text": "YUPELRI logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "621fb386-a189-459f-a9b6-7d87b85a9c60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.85,
        "x": 0.07,
        "y": 0.53
      },
      "kind": "list",
      "text": "FDA-approved for maintenance treatment of COPD\nFirst and only once-daily, LAMA (long-acting muscarinic agent) nebulized maintenance medicine for COPD\nCo-promotion agreement with VIATRISTM (35% / 65% Profit Share)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5098584d-1b41-4a0c-9012-c9e93a96e324",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "d5542c65-e352-4522-bba8-062503c55e06",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Future Vision (Gain)",
      "beatSlug": "transformation-tale-future-vision-gain",
      "evidence": "Slides 6-19 present the company's vision and growth opportunities",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}